Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis.

ABSTRACT: Mycobacterium tuberculosis has been infecting millions of people worldwide over the years, causing tuberculosis. Drugs targeting distinct cellular mechanisms including synthesis of the cell wall, lipids, proteins, and nucleic acids in Mtb are currently being used for the treatment of TB. Although extensive research is being carried out at the molecular level in the infected host and pathogen, the identification of suitable drug targets and drugs remains under explored. Pranlukast, an allosteric inhibitor of MtArgJ (Mtb ornithine acetyltransferase) has previously been shown to inhibit the survival and virulence of Mtb. The main objective of this study was to identify the altered metabolic pathways and biological processes associated with the differentially expressed metabolites by PRK in Mt

SUBMITTER: Yelamanchi SD 

PROVIDER: S-EPMC8911922 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature